BioGene Therapeutics Welcomes Professor Mirela Delibegovic, FRSE to Its Scientific Advisory Board
PreveCeutical Medical announced that its subsidiary BioGene Therapeutics has appointed Professor Mirela Delibegovic, FRSE to its Scientific Advisory Board effective November 19, 2024. The company, which focuses on developing preventive and curative therapies using organic and nature-identical products, expects to benefit from Delibegovic's expertise in obesity and diabetes physiology and signaling research to advance their therapeutic programs in metabolic health.
PreveCeutical Medical ha annunciato che la sua filiale BioGene Therapeutics ha nominato la Professoressa Mirela Delibegovic, FRSE, nel suo Consiglio Scientifico a partire dal 19 novembre 2024. L'azienda, che si concentra sullo sviluppo di terapie preventive e curative utilizzando prodotti organici e identici alla natura, prevede di beneficiare dell'esperienza di Delibegovic nella fisiologia e nella ricerca dei segnali di obesità e diabete per avanzare i loro programmi terapeutici nella salute metabolica.
PreveCeutical Medical anunció que su subsidiaria BioGene Therapeutics ha designado a la profesora Mirela Delibegovic, FRSE, para su Consejo Asesor Científico a partir del 19 de noviembre de 2024. La empresa, que se centra en el desarrollo de terapias preventivas y curativas utilizando productos orgánicos e idénticos a la naturaleza, espera beneficiarse de la experiencia de Delibegovic en fisiología de la obesidad e investigación de señales de diabetes para avanzar en sus programas terapéuticos en salud metabólica.
프레브시유티컬 메디컬은 자회사 바이오진 치료제가 미렐라 데리베고비치 교수(FRSE)를 2024년 11월 19일부터 과학 자문 위원회에 임명했다고 발표했습니다. 생물학적이며 자연과 동일한 제품을 이용한 예방 및 치료 요법 개발에 주력하는 이 회사는 비만과 당뇨병 생리학 및 신호 연구에 대한 그녀의 전문성 덕분에 대사 건강에 대한 치료 프로그램을 발전시키는 데 혜택을 볼 것으로 기대하고 있습니다.
PreveCeutical Medical a annoncé que sa filiale BioGene Therapeutics a nommé la Professeure Mirela Delibegovic, FRSE, dans son Conseil Consultatif Scientifique à compter du 19 novembre 2024. L'entreprise, qui se concentre sur le développement de thérapies préventives et curatives utilisant des produits biologiques et identiques à ceux de la nature, s'attend à bénéficier de l'expertise de Delibegovic en physiologie de l'obésité et en recherche de signalisation pour faire avancer ses programmes thérapeutiques en santé métabolique.
PreveCeutical Medical gab bekannt, dass ihre Tochtergesellschaft BioGene Therapeutics Professorin Mirela Delibegovic, FRSE, mit Wirkung vom 19. November 2024 in ihren Wissenschaftlichen Beirat berufen hat. Das Unternehmen, das sich auf die Entwicklung von präventiven und heilenden Therapien mit biologischen und naturidentischen Produkten konzentriert, erwartet, von Delibegovics Fachwissen in der Physiologie und Signalforschung zu Fettleibigkeit und Diabetes zu profitieren, um ihre therapeutischen Programme im Bereich der metabolischen Gesundheit voranzubringen.
- Strategic appointment of an expert in obesity and diabetes research
- Enhancement of scientific expertise for therapeutic program development
- None.
Vancouver, British Columbia--(Newsfile Corp. - November 21, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed Prof. Mirela Dellbegovic, FRSE to the Scientific Advisory Board effective on 19 November, 2024.
Stephen Van Deventer, CEO of BioGene, commented:
"We are honored to welcome Professor Mirela Delibegovic to our Scientific Advisory Board. Mirela's extensive research in obesity and diabetes physiology and signaling, coupled with her leadership in translational discovery, will provide invaluable insights as we advance our therapeutic programs. Her expertise aligns seamlessly with BioGene's mission to develop innovative solutions for metabolic health challenges."
About Professor Mirela Delibegovic:
Professor Delibegovic is a distinguished academic and entrepreneurial research leader in biomedical sciences. She currently holds the Regius Chair of Physiology at the University of Aberdeen and serves as the Director of the Aberdeen Cardiovascular and Diabetes Centre. With over 25 years of experience in the cardiometabolic field, her research focuses on the molecular mechanisms underlying diabetes, obesity, and their complications, with an emphasis on translational discovery and therapeutic development.
Throughout her career, Professor Delibegovic has initiated and developed constructive collaborations leading to key publications, significant sustainable funding, and impactful translational research outcomes. Work developed through these collaborations was recently highlighted by the United Nations Academic Impact publication as the example of a successful collaboration between academia and industry. She has been recognized with numerous awards, including being elected a Fellow of the Royal Society of Edinburgh (FRSE) in 2022. Her leadership extends to various national and international committees, reflecting her commitment to advancing biomedical research and innovation.
Professor Delibegovic remarked on her appointment:
"I am delighted to join BioGene's Scientific Advisory Board and collaborate with a team dedicated to addressing critical unmet medical needs in cardiometabolic health. I look forward to contributing my expertise to support BioGene's innovative therapeutic initiatives."
About PreveCeutical Medical Inc.
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit www.PreveCeutical.com, follow us on Twitter: http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.
About BioGene Therapeutics Inc.
BioGene Therapeutics Inc. ("BioGene") is a Texas-based life sciences company focused on advancing innovative therapies in metabolic health and gene-based treatments. As a key component of BioGene's expansion, BioGene Australia operates as a wholly-owned subsidiary of BioGene in Texas, leveraging the strategic benefits of Australia's
On Behalf of the Board of Directors,
PreveCeutical Medical Inc. & BioGene Therapeutics Inc.
"Stephen Van Deventer"
Chairman & Chief Executive Officer
For further information, please contact:
Stephen Van Deventer
(604) 306-9669
info@PreveCeutical.com
Forward-Looking Statements:
This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding receipt of regulatory and other consents and approvals for the Acquisition; PreveCeutical, PreveCeutical Australia, and BioGene completing the Acquisition as contemplated by the Agreement; PreveCeutical receiving the necessary regulatory and other consents and approvals for the Distribution; and PreveCeutical completing the Distribution as contemplated above. The forward-looking statements reflect management's current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements including adverse market conditions and other factors beyond the control of the parties. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include general market conditions and other factors beyond the control of the Company; regulations and policies affecting the biotechnology or pharmaceutical industry adversely affecting the future results or performance of PreveCeutical or BioGene; the Company's failure to obtain the required consents and approvals for the Acquisition and the Distribution; and the Company determining that the Distribution is not an optimal strategy following tax and business consultations. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/230766
FAQ
When did Professor Mirela Delibegovic join PreveCeutical Medical's (PRVCF) Scientific Advisory Board?
What expertise does Professor Delibegovic bring to PreveCeutical Medical (PRVCF)?
What is BioGene Therapeutics' relationship with PreveCeutical Medical (PRVCF)?
